ROCKVILLE, Md., July 30, 2020 \/PRNewswire\/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAVTechnology Platform, today announced that it will host a conference call on Thursday, August 6, 2020, at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2020, and recent operational highlights.<\/p>\n
To access the live call by phone, dial (800) 708-4539 (domestic) or (800) 619-6396 (international) and enter the passcode 49857700. To access a live or recorded webcast of the call, please visit the Investors section of the REGENXBIO website at http:\/\/www.regenxbio.com<\/a>. The recorded webcast will be available for approximately 30 days following the call.<\/p>\n AboutREGENXBIO Inc.<\/p>\n REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.<\/p>\n Contacts:<\/p>\n Tricia TruehartInvestor Relations and Corporate Communications347-926-7709[emailprotected]<\/p>\n Investors:Eleanor Barisser, 212-600-1902[emailprotected] <\/p>\n Media:David Rosen, 212-600-1902[emailprotected] <\/p>\n SOURCE REGENXBIO Inc.<\/p>\n http:\/\/www.regenxbio.com<\/a><\/p>\n <\/p>\n Read the rest here: <\/p>\n REGENXBIO To Host Conference Call on August 6 to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights - PRNewswire<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" ROCKVILLE, Md., July 30, 2020 \/PRNewswire\/ -- REGENXBIO Inc. Continue reading